JOP20180071A1 - استخدام مشتقات أمينو ألكيل بنزوثيازبين - Google Patents
استخدام مشتقات أمينو ألكيل بنزوثيازبينInfo
- Publication number
- JOP20180071A1 JOP20180071A1 JOP/2018/0071A JOP20180071A JOP20180071A1 JO P20180071 A1 JOP20180071 A1 JO P20180071A1 JO P20180071 A JOP20180071 A JO P20180071A JO P20180071 A1 JOP20180071 A1 JO P20180071A1
- Authority
- JO
- Jordan
- Prior art keywords
- healthcare corporation
- dyslipidemia
- preventing
- present disclosure
- pharmaceutically acceptable
- Prior art date
Links
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Resins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
يتعلق الكشف الحالي بتركيبة صيدلانية للوقاية من أو علاج مرض الكبد الدهني غير الكحولي أو اضطراب شحوم الدم تشتمل على مشتق أمينو ألكيل بنزوثيازبين أو ملح مقبول صيدلانياً منه كمكون نشط.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170092852A KR101844184B1 (ko) | 2017-07-21 | 2017-07-21 | 아미노알킬벤조티아제핀 유도체의 용도 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JOP20180071A1 true JOP20180071A1 (ar) | 2019-01-21 |
| JOP20180071B1 JOP20180071B1 (ar) | 2023-09-17 |
Family
ID=61976164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2018/0071A JOP20180071B1 (ar) | 2017-07-21 | 2018-07-22 | استخدام مشتقات أمينو ألكيل بنزوثيازبين |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11202783B2 (ar) |
| EP (1) | EP3654987B1 (ar) |
| JP (1) | JP6946477B2 (ar) |
| KR (1) | KR101844184B1 (ar) |
| CN (1) | CN110785173B (ar) |
| AR (1) | AR112283A1 (ar) |
| AU (1) | AU2018303109B2 (ar) |
| CA (1) | CA3067482C (ar) |
| JO (1) | JOP20180071B1 (ar) |
| TW (2) | TWI784232B (ar) |
| WO (1) | WO2019017724A1 (ar) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202000486T1 (it) | 2010-11-04 | 2020-11-10 | Albireo Ab | Inibitori di ibat per il trattamento di malattie del fegato |
| KR101844184B1 (ko) | 2017-07-21 | 2018-04-02 | 씨제이헬스케어 주식회사 | 아미노알킬벤조티아제핀 유도체의 용도 |
| PE20210136A1 (es) | 2018-06-20 | 2021-01-21 | Albireo Ab | Formulacion farmaceutica de odevixibat |
| RS63899B1 (sr) | 2019-02-06 | 2023-02-28 | Albireo Ab | Benzotiadiazepinska jedinjenja i njihova upotreba kao modulatora žučnih kiselina |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| CN114761079B (zh) | 2019-12-04 | 2024-05-28 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| ES2973355T3 (es) | 2019-12-04 | 2024-06-19 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar |
| CA3158276A1 (en) | 2019-12-04 | 2021-06-10 | Per-Goran Gillberg | Benzothia(di)azepine compounds and their use as bile acid modulators |
| JP2024500309A (ja) | 2020-12-04 | 2024-01-09 | アルビレオ エービー | ベンゾチア（ジ）アゼピン化合物および胆汁酸モジュレータとしてのその使用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9423172D0 (en) | 1994-11-17 | 1995-01-04 | Wellcom Foundation The Limited | Hypolipidemic benzothiazepines |
| SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
| CA2417492A1 (en) * | 2000-08-01 | 2003-01-28 | Shionogi & Co., Ltd. | Preventives or remedies for obesity or fatty liver |
| GB0121337D0 (en) * | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
| GB0216321D0 (en) * | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Therapeutic treatment |
| GB0304194D0 (en) * | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| SMT202000486T1 (it) * | 2010-11-04 | 2020-11-10 | Albireo Ab | Inibitori di ibat per il trattamento di malattie del fegato |
| JP2012224590A (ja) | 2011-04-21 | 2012-11-15 | Shuichi Kihata | コレステロール低下剤−胆汁酸腸管吸収抑制物質 |
| KR20150088038A (ko) * | 2014-01-23 | 2015-07-31 | 동국대학교 산학협력단 | 아미드 유도체 화합물 및 이의 용도 |
| KR101498218B1 (ko) * | 2014-09-23 | 2015-03-12 | 연세대학교 산학협력단 | 신규한 펜타디에노일 피페리딘 유도체 및 그의 용도 |
| KR101674806B1 (ko) | 2014-10-20 | 2016-11-10 | 씨제이헬스케어 주식회사 | 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도 |
| EP3012252A1 (en) * | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| KR101844184B1 (ko) | 2017-07-21 | 2018-04-02 | 씨제이헬스케어 주식회사 | 아미노알킬벤조티아제핀 유도체의 용도 |
-
2017
- 2017-07-21 KR KR1020170092852A patent/KR101844184B1/ko active Active
-
2018
- 2018-07-20 US US16/631,611 patent/US11202783B2/en active Active
- 2018-07-20 CA CA3067482A patent/CA3067482C/en active Active
- 2018-07-20 WO PCT/KR2018/008211 patent/WO2019017724A1/en unknown
- 2018-07-20 EP EP18835549.9A patent/EP3654987B1/en active Active
- 2018-07-20 TW TW109101070A patent/TWI784232B/zh active
- 2018-07-20 JP JP2019571703A patent/JP6946477B2/ja active Active
- 2018-07-20 AU AU2018303109A patent/AU2018303109B2/en active Active
- 2018-07-20 TW TW107125174A patent/TWI752251B/zh active
- 2018-07-20 AR ARP180102041 patent/AR112283A1/es unknown
- 2018-07-20 CN CN201880042435.9A patent/CN110785173B/zh active Active
- 2018-07-22 JO JOP/2018/0071A patent/JOP20180071B1/ar active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110785173B (zh) | 2023-01-10 |
| TW202019891A (zh) | 2020-06-01 |
| CN110785173A (zh) | 2020-02-11 |
| KR101844184B1 (ko) | 2018-04-02 |
| JP6946477B2 (ja) | 2021-10-06 |
| EP3654987B1 (en) | 2022-08-31 |
| TWI752251B (zh) | 2022-01-11 |
| AU2018303109B2 (en) | 2021-08-12 |
| CA3067482C (en) | 2023-03-14 |
| CA3067482A1 (en) | 2019-01-24 |
| WO2019017724A1 (en) | 2019-01-24 |
| AR112283A1 (es) | 2019-10-09 |
| TWI784232B (zh) | 2022-11-21 |
| JP2020525464A (ja) | 2020-08-27 |
| EP3654987A4 (en) | 2021-04-28 |
| US11202783B2 (en) | 2021-12-21 |
| TW201908298A (zh) | 2019-03-01 |
| US20200147101A1 (en) | 2020-05-14 |
| AU2018303109A1 (en) | 2019-12-19 |
| JOP20180071B1 (ar) | 2023-09-17 |
| EP3654987A1 (en) | 2020-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20180071A1 (ar) | استخدام مشتقات أمينو ألكيل بنزوثيازبين | |
| PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| MX2016016593A (es) | Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos. | |
| WO2016164675A8 (en) | Substituted quinazoline compounds and methods of use thereof | |
| MX380928B (es) | Inhibidores de kras g12c. | |
| TN2017000075A1 (en) | Compounds and compositions as raf kinase inhibitors | |
| PH12019502150A1 (en) | Compounds and methods for the treatment of parasitic diseases | |
| EP3613419A4 (en) | PHARMACEUTICAL COMPOSITION WITH INDIRUBY DERIVATIVE AS THE ACTIVE SUBSTANCE | |
| BR112016026552A8 (pt) | derivados de carboxamida, seus usos, composição farmacêutica, e combinação | |
| EP2987786A4 (en) | AMIDOPYRIDINOL DERIVATIVE OR PHARMACEUTICAL, SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE SUBSTANCE | |
| EA201691741A1 (ru) | Фармацевтическая композиция | |
| MD4563B1 (ro) | Produs de comicronizare cu conţinut de acetat de ulipristal | |
| TN2016000491A1 (en) | Carboxamide derivatives. | |
| EP3138834A4 (en) | Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient | |
| MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
| EP3352750A4 (en) | Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| WO2016006975A3 (en) | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof | |
| MX2019008338A (es) | Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco. | |
| WO2016006974A3 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | |
| EP3785715A4 (en) | Pharmaceutical composition comprising ibrutinib as effective ingredient for preventing or treating degenerative brain disease | |
| MX386902B (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
| WO2016069542A3 (en) | Lactone compounds and methods of making and using same | |
| ZA201801839B (en) | Pharmaceutical composition for preventing and treating liver diseases, containing, as active ingredient, cromolyn or pharmaceutically acceptable salt thereof | |
| EP3120848A4 (en) | Therapeutic/preventive agent containing coumarin derivative as active ingredient |